Figure 3

LAMTOR5 upregulates NF-κB to promote the transcription of GLUT1 in liver cancer. (A) The effect of LAMTOR5 and/or NF-κB inhibitor (PDTC) on wild type (wt) and mutant (mut) GLUT1 promoter was evaluated. (B) The level of NF-κB and GLUT1 in liver cancer cells under the administration of LAMTOR5 overexpression and/or NF-κB/p65 siRNAs was evaluated through Western blotting. ImageQuant 5.2 software (GE Healthcare, UK) was used to quantify the bands of GLUT1, NF-κB or LAMTOR5 relative to β-actin. ***P < 0.001.

© De Gruyter